ProPhase Labs Files 8-K Report
Ticker: PRPH · Form: 8-K · Filed: Aug 19, 2025 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
ProPhase Labs filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On August 19, 2025, ProPhase Labs, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates ProPhase Labs is providing updated information to the SEC, which could include financial statements or other material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events or financial distress.
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer of the 8-K report
- August 19, 2025 (date) — Date of the earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 23-2577138 (identifier) — I.R.S. Employer Identification No.
- 626 RXR Plaza , 6th Floor Uniondale , New York 11556 (address) — Address of principal executive offices
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The provided excerpt indicates that 'Financial Statements and Exhibits' are part of the filing, but does not specify which ones.
What 'Other Events' are being reported by ProPhase Labs, Inc. in this filing?
The excerpt lists 'Other Events' as an item information category but does not provide details on what those events are.
What is the purpose of a Regulation FD Disclosure in this context?
A Regulation FD Disclosure ensures that material information is broadly disseminated to the public, preventing selective disclosure.
When was ProPhase Labs, Inc. incorporated, and in which state?
ProPhase Labs, Inc. was incorporated in Delaware.
What is the principal executive office address for ProPhase Labs, Inc.?
The principal executive office address is 626 RXR Plaza, 6th Floor, Uniondale, New York 11556.
Filing Stats: 890 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2025-08-19 08:00:17
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 34KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001641172-25-024730.txt ( ) — 251KB
- prph-20250819.xsd (EX-101.SCH) — 3KB
- prph-20250819_lab.xml (EX-101.LAB) — 33KB
- prph-20250819_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 PROPHASE LABS, INC. (Exact name of Company as specified in its charter) Delaware 000-21617 23-2577138 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 626 RXR Plaza , 6th Floor Uniondale , New York 11556 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (516) 989-0763 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure On August 19, 2025, the Company issued a press release announcing that the Company filed the Definitive Proxy Statement with the SEC on Friday, August 15, 2025, received a "no further comments" letter from the SEC's Division of Corporation Finance Office of Life Sciences, indicating that the Staff had completed the review of the Preliminary Proxy Statement of Schedule 14A, on Monday, August 18, 2025, and adjourned the Special Meeting of Shareholders from Friday, August 29, 2005 to Tuesday, September 9, 2025, at 4:00 p.m. Eastern Time, at 273MerrickRoad, Lynbrook, NY11563. The additional time ensures proper dissemination of the definitive proxy materials and continued compliance with applicable regulations. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01 Other Events The information set forth under Item 7.01 above is incorporated herein by reference. Forward-Looking This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K other than statements of historical fact are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the Company's ability to regain compliance with Nasdaq listing standards or receive additional time from Nasdaq to regain compliance if necessary. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and the negative of such terms or other similar expressions may identify forward-looking based on the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any forward-look